#USA #Fremont #Alzheimer’s #Alamar Biosciences #NULISAqpcr

Alamar Biosciences Introduces NULISAqpcr™ BD-pTau217

Alamar Biosciences has made headlines with the launch of its groundbreaking test, the NULISAqpcr™ BD-pTau217. This innovative approach marks a significant milestone in the quest for early detection of Alzheimer’s disease and other tauopathies, which are neurodegenerative diseases characterized by abnormal aggregation of tau protein in the brain.

On October 10, 2025, the company announced that the NULISAqpcr™ BD-pTau217 test would provide unprecedented sensitivity and specificity in quantifying phosphorylated tau 217 (pTau217) through a simple blood test, eliminating the need for more invasive procedures such as cerebrospinal fluid (CSF) collection or PET imaging. This not only streamlines the testing process but also makes it more acceptable for wide-scale population studies and longitudinal clinical trials.

Dr. Yuling Luo, the founder and CEO of Alamar Biosciences, stated, "The NULISAqpcr BD-pTau217 brings a new perspective on the quantification of CNS biomarkers. By filtering out noise from peripheral tau sources, researchers can now detect significant changes in the brain earlier and with greater accuracy."

A Game Changer for Alzheimer’s Research

The NULISAqpcr BD-pTau217 test is designed to serve as a transformative tool in Alzheimer’s research. Tau 217 is recognized as a crucial biomarker in identifying Alzheimer’s pathology. This revolutionary test is the first of its kind to offer a singleplex solution derived from brain activity, establishing a new standard for the accuracy and specificity of central nervous system biomarkers.

Notable figures in the neurological community have endorsed the test's potential. Dr. Jonathan Schott, a professor of neurology at University College London, praised the performance of Alamar's brain-specific pTau217 tests, suggesting they perform at least as well as established plasma tau217 tests while requiring fewer samples classified as indeterminate.

This might be critically important as more accurate assessments enable researchers to pinpoint asymptomatic individuals with high levels of Alzheimer’s pathology, who could then be recruited for clinical trials of disease-modifying therapies.

Testing and Processing Capabilities

The NULISAqpcr BD-pTau217 test operates on Alamar's proprietary NULISA™ platform and efficiently processes non-invasive sample types such as plasma, serum, and dried blood spots. It allows for direct measurement of pTau217 without the drawbacks of traditional methods, making it an essential tool in contemporary neurodegenerative disease research.

Utilizing the ARGO™ HT system, the automated workflow can handle more than 220 samples a day, positioning it perfectly for high-throughput analysis within patient cohorts or population studies.

Collaboration with the neuroscience community remains a core mission for Alamar Biosciences as they aim to unveil insights into biomarkers that can accelerate progress in Alzheimer’s research and other related conditions.

For more information about Alamar Biosciences and their revolutionary products, visit alamarbio.com.

About Alamar Biosciences, Inc.

Alamar Biosciences is a private biological sciences company dedicated to enhancing precision proteomics for early disease detection. Their proprietary NULISA™ platform, combined with ARGO™ HT, harnesses cutting-edge advancements in genomics, achieving detection sensitivities measured in attomoles—far exceeding the sensitivity of any protein detection technology currently on the market. For further details, please check alamarbio.com.